Types of Paper

  1. Commentary – invited article, usually a thought-provoking idea or opinion on selected topics or brief report from members of the Editorial Board, International Editorial Advisory Board or reviewers. The commentary is usually one or two pages (800 or 1,600 words) with up to 20 references, may include one figure or table, covering issues surrounding medical ethics, policies, and comment on one or more articles that appear in the same issue. However, unsolicited commentaries may be submitted and undergo the peer review process.
  2. Review article – invited article, containing the current state of the research of a particular topic, but we will consider unsolicited material. Please send us a pre-submission inquiry before writing a review article for the Journal. Proposals for topics are best submitted in the form of a two-page outline of the planned manuscript in order to discuss its content at an early stage. All review articles undergo the same peer review and editorial process as original research reports. Review articles should contain a maximum of 6,500 words including an abstract of maximum 250 words and 60 references. Different types of review articles are published in GaBI Journal, among which some have a more specific format or purpose, such as basic research-related reviews; legal and ethical issues; seminal studies; clinical commentary; report from a roundtable or a workshop; statement of working group; special article; etc.
    Conflicts of Interest: because the essence of review articles is selection and interpretation of the literature, GaBI Journal expects that the authors of such articles will not have significant financial associations with a company (or its competitor) that makes a product discussed in the article.
  3. Meta-analysis – covering results of several studies that address a set of related research topics.
  4. Original research – scientific papers investigating all aspects of generics and biosimilars development (including manufacturing and production technology) and usage (including clinical research and risk management). Original research papers must not exceed 5,000 words including an abstract of maximum 250 words and should not include more than six illustrations and tables. Note that each separate part of a figure (a, b, etc.) counts as an illustration. Up to 40 references are permitted. When reporting the results of a randomised controlled trial, author(s) should use the CONSORT statement as a guide in preparing the manuscript. If the authors consider that their manuscript needs to be longer than the mentioned limit or contain more figures or tables, they can explain their reasons in the cover letter to the Editor-in-Chief.
  5. Short communications – short report in one-page format providing key messages with elaborate background information or with the full report available on the website. The title should accurately, clearly and concisely reflect the content of the paper. Papers submitted should contain innovative concepts, experimental observations and methods, or theoretical developments on any subjects in the field of generics and biosimilars science. Short communications are limited to one printed page (800 words including an abstract of 24 words, five references with one figure or table) and deal with significant findings worthy of urgent publication. It is preferable that the text is divided into the following sections: Introduction, Experimental (or Theoretical), Results, and Discussion. Results and Discussion sections may be combined, if desired.
  6. Letters to the Editor – established as a proactive discussion platform, allowing readers’ responses or reactions to articles published in GaBI Journal, this is the place to publish concise articles, such as reports of novel cases. The articles must not exceed 800 words including an abstract of 24 words, five references and one figure or table, and should be addressed to the Editor-in-Chief. Letters submitted may be subject to shortening and editorial revision. Please see specific instructions for Letters to the Editor.
  7. Perspective – articles cover a wide variety of topics of current interest in health care, medicine, regulators and the intersection between patients/stakeholders and society. We welcome submissions and proposals. Perspective articles are limited to 1,600 to 2,400 words and usually include one figure. There is a maximum of 20 references.
  8. Special Reports are miscellaneous articles of special interest to the medical community. They are limited to 4,100 words. Health policy reports are always solicited, and unsolicited manuscripts can be considered. Please send us a pre-submission inquiry before submitting a manuscript.
  9. Rhythm articles are accounts of personal experiences or descriptions of material from outside the usual areas of generic and biosimilar medicines. It gives a lighter look at what is happening worldwide.
  10. Other manuscripts covering issues on legal/regulatory/guidelines, education, and patient-oriented information are welcome.

For manuscripts written based on a survey, please see below instructions:
– Describe the questionnaire methods
– How were/who the questions selected?
– How many questionnaires were sent?
– Who/how were recipients selected to get them?
– Was there any pre-testing of final questions?
– How many mailings (post, fax, emails, etc.) were used?
– What languages?
– Any reimbursement offered/paid to respondents?

Filler Photographs

Filler photographs are unsolicited photographs. It can be unrelated to the contents of the Journal that are published. There are no restrictions on the subject of photograph, however, photographs of recognisable people are not published. Photograph typical for GaBI Journal, or related to generics, receptors, epos, etc., are welcome.


You will be notified by email once the submitted photo has been reviewed by our editors and is selected for publication.

Submit the photo together with your manuscript.

Source URL: https://gabi-journal.net/gabi-journal/information-for-authors/types-of-paper

Generics and Biosimilars Initiative (GaBI)
Tel: +32 474989572 | Fax: +32 14 583 048